Martek Says IoM Report On Infant Formula Will Not Impact Sales
This article was originally published in The Tan Sheet
Executive Summary
Recommendations in the Institute of Medicine's recent report on evaluating new infant formula ingredients will not affect currently marketed products containing Martek's docosahexaenoic acid (DHA) and arachidonic acid (ARA)
You may also be interested in...
Probiotics, Fatty Acids Are Case Studies In IoM Infant Formula Report
New infant formula ingredients should undergo a two-step evaluation process to evaluate potential toxicity, the Institute of Medicine recommends in a report released March 1. The report outlines details the addition of fatty acids and probiotics as case studies
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands